Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Rises By 47.2%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 25,600 shares, an increase of 47.2% from the November 30th total of 17,390 shares. Approximately 4.1% of the shares of the stock are short sold. Based on an average daily volume of 13,432 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily volume of 13,432 shares, the days-to-cover ratio is currently 1.9 days. Approximately 4.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 406,000 shares of the company’s stock, valued at approximately $335,000. Armistice Capital LLC owned 90.22% of CNS Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 14.02% of the company’s stock.

CNS Pharmaceuticals Stock Down 13.9%

NASDAQ:CNSP opened at $5.31 on Tuesday. The firm has a market cap of $3.29 million, a PE ratio of -0.17 and a beta of 2.62. CNS Pharmaceuticals has a 12 month low of $4.93 and a 12 month high of $114.00. The company’s 50-day moving average price is $6.99 and its two-hundred day moving average price is $7.97.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($5.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.63) by $0.87.

Analyst Upgrades and Downgrades

CNSP has been the topic of a number of recent research reports. Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Friday, September 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut CNS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 5th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CNS Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.